NO326356B1 - Kombinasjon av tiazolidindion og sulfonylurea samt anvendelse derav og farmasoytisk blanding. - Google Patents

Kombinasjon av tiazolidindion og sulfonylurea samt anvendelse derav og farmasoytisk blanding. Download PDF

Info

Publication number: NO326356B1
Authority: NO; Norway
Prior art keywords: compound; pharmaceutically acceptable; tautomeric form; acceptable derivative; diabetes mellitus
Prior art date: 1997-07-18

Application number

NO20000229A

Other languages

English (en)

Norwegian (no)

Other versions

NO20000229L (no

NO20000229D0 (no

Inventor

Stephen Alistair Smith

Robin Edwin Buckingham

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-18

Filing date

2000-01-17

Publication date

2008-11-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10816177&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO326356(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-01-17 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2000-01-17 Publication of NO20000229L publication Critical patent/NO20000229L/no

2000-01-17 Publication of NO20000229D0 publication Critical patent/NO20000229D0/no

2008-11-17 Publication of NO326356B1 publication Critical patent/NO326356B1/no

Links

ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title claims description 16
229940100389 Sulfonylurea Drugs 0.000 title claims description 14
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
229940123464 Thiazolidinedione Drugs 0.000 title description 7
150000001875 compounds Chemical class 0.000 claims description 80
206010012601 diabetes mellitus Diseases 0.000 claims description 30
-1 carburamide Chemical compound 0.000 claims description 23
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 14
229960004580 glibenclamide Drugs 0.000 claims description 14
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 14
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 13
229960000346 gliclazide Drugs 0.000 claims description 13
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims description 12
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
229960001381 glipizide Drugs 0.000 claims description 12
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 12
229960002277 tolazamide Drugs 0.000 claims description 12
OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims description 12
229960005371 tolbutamide Drugs 0.000 claims description 12
229960004346 glimepiride Drugs 0.000 claims description 10
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 10
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 9
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 9
229960001466 acetohexamide Drugs 0.000 claims description 9
VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 claims description 9
229960001761 chlorpropamide Drugs 0.000 claims description 9
229960001764 glibornuride Drugs 0.000 claims description 9
RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 claims description 9
229950008402 glisentide Drugs 0.000 claims description 9
NSJYMFYVNWVGON-UHFFFAOYSA-N glisentide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 claims description 9
229950005319 glisolamide Drugs 0.000 claims description 9
GZKDXUIWCNCNBJ-UHFFFAOYSA-N glisolamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 claims description 9
229960003236 glisoxepide Drugs 0.000 claims description 9
ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 claims description 9
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 9
229960002354 repaglinide Drugs 0.000 claims description 9
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
229940079593 drug Drugs 0.000 claims description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
239000004202 carbamide Substances 0.000 claims description 6
235000013877 carbamide Nutrition 0.000 claims description 6
229940045136 urea Drugs 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 56
102000004877 Insulin Human genes 0.000 description 28
108090001061 Insulin Proteins 0.000 description 28
229940125396 insulin Drugs 0.000 description 28
230000001235 sensitizing effect Effects 0.000 description 26
239000000203 mixture Substances 0.000 description 20
229940122199 Insulin secretagogue Drugs 0.000 description 19
239000003795 chemical substances by application Substances 0.000 description 14
208000001072 type 2 diabetes mellitus Diseases 0.000 description 13
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 9
238000000034 method Methods 0.000 description 7
206010022489 Insulin Resistance Diseases 0.000 description 4
239000013543 active substance Substances 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
208000017169 kidney disease Diseases 0.000 description 4
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 4
229960005095 pioglitazone Drugs 0.000 description 4
239000003826 tablet Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
235000008504 concentrate Nutrition 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
150000002688 maleic acid derivatives Chemical class 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
229940122355 Insulin sensitizer Drugs 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
239000003708 ampul Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229960001641 troglitazone Drugs 0.000 description 2
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229960003362 carbutamide Drugs 0.000 description 1
VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
229950009226 ciglitazone Drugs 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
229950002375 englitazone Drugs 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
229950010170 epalrestat Drugs 0.000 description 1
CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000004104 gestational diabetes Diseases 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
239000003906 humectant Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
229940126904 hypoglycaemic agent Drugs 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960001729 voglibose Drugs 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20000229A 1997-07-18 2000-01-17 Kombinasjon av tiazolidindion og sulfonylurea samt anvendelse derav og farmasoytisk blanding. NO326356B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9715306A GB9715306D0 (en)	1997-07-18	1997-07-18	Novel method of treatment
PCT/GB1998/002109 WO1999003476A1 (en)	1997-07-18	1998-07-16	Treatment of diabetes with thiazolidinedione and sulphonylurea

Publications (3)

Publication Number	Publication Date
NO20000229L NO20000229L (no)	2000-01-17
NO20000229D0 NO20000229D0 (no)	2000-01-17
NO326356B1 true NO326356B1 (no)	2008-11-17

Family

ID=10816177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20000229A NO326356B1 (no)	1997-07-18	2000-01-17	Kombinasjon av tiazolidindion og sulfonylurea samt anvendelse derav og farmasoytisk blanding.

Country Status (41)

Country	Link
EP (1)	EP0998291B2 (da)
JP (2)	JP2001510158A (da)
KR (1)	KR100680667B1 (da)
CN (1)	CN1264302A (da)
AP (1)	AP1318A (da)
AR (2)	AR016768A1 (da)
AT (1)	ATE366577T1 (da)
AU (1)	AU743269B2 (da)
BG (1)	BG64892B1 (da)
BR (1)	BR9810904A (da)
CA (1)	CA2297115C (da)
CO (1)	CO4940422A1 (da)
CY (1)	CY1107745T1 (da)
CZ (1)	CZ302668B6 (da)
DE (1)	DE69838066T3 (da)
DK (1)	DK0998291T4 (da)
DZ (1)	DZ2564A1 (da)
EA (1)	EA003303B1 (da)
ES (1)	ES2290989T5 (da)
GB (1)	GB9715306D0 (da)
HK (1)	HK1029272A1 (da)
HU (1)	HU229119B1 (da)
ID (1)	ID24198A (da)
IL (1)	IL134045A0 (da)
IN (1)	IN189035B (da)
MA (1)	MA26522A1 (da)
MY (1)	MY138246A (da)
NO (1)	NO326356B1 (da)
NZ (3)	NZ515555A (da)
OA (1)	OA11632A (da)
PE (1)	PE99799A1 (da)
PL (2)	PL199125B1 (da)
PT (1)	PT998291E (da)
SI (1)	SI0998291T2 (da)
SK (2)	SK288053B6 (da)
TR (1)	TR200000135T2 (da)
TW (1)	TW586926B (da)
UA (1)	UA70302C2 (da)
UY (1)	UY25103A1 (da)
WO (1)	WO1999003476A1 (da)
ZA (1)	ZA986365B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1897547A1 (en) *	1999-07-13	2008-03-12	Medicure Inc.	Use of pyridoxal phosphate derivatives for the treatment of diabetes and related complications
EP1832291A3 (en) *	1999-07-13	2009-11-04	Medicure Inc.	use of pyridoxal phosphate for the treatment of diabetes and related complications
US6586438B2 (en)	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
US20010036479A1 (en)	2000-01-14	2001-11-01	Gillian Cave	Glyburide composition
US7964216B2 (en)	2001-01-12	2011-06-21	Sun Pharma Advanced Research Company Limited	Spaced drug delivery system
RU2359661C2 (ru) *	2003-10-31	2009-06-27	Такеда Фармасьютикал Компани Лимитед	Твердый препарат
JP2008019169A (ja) *	2004-10-25	2008-01-31	Osaka Univ	新規ｐｐａｒ調節剤およびそのスクリーニング方法
NZ569071A (en)	2005-12-22	2011-01-28	Takeda Pharmaceutical	Solid preparation containing an insulin sensitizer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5522636A (en) *	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
JPS5697277A (en) *	1980-01-07	1981-08-05	Takeda Chem Ind Ltd	Thiazolidine derivative
JPS6051189A (ja) *	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
US4582839A (en) *	1984-03-21	1986-04-15	Takeda Chemical Industries, Ltd.	2,4-thiazolidinediones
CN1003445B (zh) *	1984-10-03	1989-03-01	武田药品工业株式会社	噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) *	1985-06-10	1994-01-05	武田薬品工業株式会社	チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) *	1986-07-24	1989-03-14	Takeda Chemical Industries, Ltd.	Method for producing thiazolidinedione derivatives
ATE186724T1 (de) *	1987-09-04	1999-12-15	Beecham Group Plc	Substituierte thiazolidindionderivate
US4791125A (en) *	1987-12-02	1988-12-13	Pfizer Inc.	Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es) *	1988-03-08	1993-05-01	Pfizer	Derivados de tiazolidinodiona hipoglicemicos
US5061717A (en) *	1988-03-08	1991-10-29	Pfizer Inc.	Thiazolidinedione hypoglycemic agents
WO1991007107A1 (en) *	1989-11-13	1991-05-30	Pfizer Inc.	Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) *	1990-12-06	1992-07-31	Terumo Corp	チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) *	1991-04-11	1993-02-02	Takeda Chemical Industries, Ltd.	Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
ES2089474T3 (es) *	1991-08-16	1996-10-01	Sandoz Ltd	Inhalador para la administracion de sustancias en polvo.
JPH06510286A (ja) *	1991-08-26	1994-11-17	ファルマシア・アンド・アップジョン・カンパニー	３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) *	1997-02-19	1999-01-12	Warner-Lambert Company	Sulfonylurea-glitazone combinations for diabetes

1997
- 1997-07-18 GB GB9715306A patent/GB9715306D0/en active Pending
1998
- 1998-07-15 DZ DZ980174A patent/DZ2564A1/xx active
- 1998-07-16 DE DE69838066T patent/DE69838066T3/de not_active Expired - Lifetime
- 1998-07-16 CN CN98807221A patent/CN1264302A/zh active Pending
- 1998-07-16 NZ NZ515555A patent/NZ515555A/xx not_active IP Right Cessation
- 1998-07-16 ES ES98935126T patent/ES2290989T5/es not_active Expired - Lifetime
- 1998-07-16 MA MA25173A patent/MA26522A1/fr unknown
- 1998-07-16 PL PL375989A patent/PL199125B1/pl unknown
- 1998-07-16 KR KR1020007000513A patent/KR100680667B1/ko not_active IP Right Cessation
- 1998-07-16 PE PE1998000631A patent/PE99799A1/es not_active Application Discontinuation
- 1998-07-16 OA OA1200000014A patent/OA11632A/en unknown
- 1998-07-16 SK SK89-2005A patent/SK288053B6/sk not_active IP Right Cessation
- 1998-07-16 AU AU84487/98A patent/AU743269B2/en not_active Expired
- 1998-07-16 SI SI9830892T patent/SI0998291T2/sl unknown
- 1998-07-16 CA CA2297115A patent/CA2297115C/en not_active Expired - Lifetime
- 1998-07-16 HU HU0003634A patent/HU229119B1/hu unknown
- 1998-07-16 TR TR2000/00135T patent/TR200000135T2/xx unknown
- 1998-07-16 EP EP98935126A patent/EP0998291B2/en not_active Expired - Lifetime
- 1998-07-16 EA EA200000141A patent/EA003303B1/ru not_active IP Right Cessation
- 1998-07-16 SK SK60-2000A patent/SK287823B6/sk not_active IP Right Cessation
- 1998-07-16 PL PL98338127A patent/PL338127A1/xx not_active Application Discontinuation
- 1998-07-16 ID IDW20000074A patent/ID24198A/id unknown
- 1998-07-16 BR BR9810904-9A patent/BR9810904A/pt not_active Application Discontinuation
- 1998-07-16 NZ NZ501256A patent/NZ501256A/xx not_active IP Right Cessation
- 1998-07-16 UA UA2000010215A patent/UA70302C2/uk unknown
- 1998-07-16 CZ CZ20000173A patent/CZ302668B6/cs not_active IP Right Cessation
- 1998-07-16 DK DK98935126.7T patent/DK0998291T4/da active
- 1998-07-16 IL IL13404598A patent/IL134045A0/xx unknown
- 1998-07-16 PT PT98935126T patent/PT998291E/pt unknown
- 1998-07-16 AP APAP/P/2000/001734A patent/AP1318A/en active
- 1998-07-16 NZ NZ520652A patent/NZ520652A/en not_active IP Right Cessation
- 1998-07-16 AT AT98935126T patent/ATE366577T1/de active
- 1998-07-16 JP JP2000502775A patent/JP2001510158A/ja not_active Withdrawn
- 1998-07-16 WO PCT/GB1998/002109 patent/WO1999003476A1/en active IP Right Grant
- 1998-07-17 UY UY25103A patent/UY25103A1/es not_active IP Right Cessation
- 1998-07-17 CO CO98040748A patent/CO4940422A1/es unknown
- 1998-07-17 ZA ZA9806365A patent/ZA986365B/xx unknown
- 1998-07-17 AR ARP980103516A patent/AR016768A1/es not_active Application Discontinuation
- 1998-07-17 MY MYPI98003290A patent/MY138246A/en unknown
- 1998-07-17 TW TW087111768A patent/TW586926B/zh not_active IP Right Cessation
- 1998-07-20 IN IN2089DE1998 patent/IN189035B/en unknown
1999
- 1999-06-18 AR ARP990102953A patent/AR019331A2/es unknown
2000
- 2000-01-17 NO NO20000229A patent/NO326356B1/no not_active IP Right Cessation
- 2000-02-08 BG BG104139A patent/BG64892B1/bg active Active
- 2000-10-24 HK HK00106765A patent/HK1029272A1/xx not_active IP Right Cessation
2005
- 2005-04-21 JP JP2005123586A patent/JP2005247865A/ja active Pending
2007
- 2007-09-27 CY CY20071101241T patent/CY1107745T1/el unknown

Also Published As

Publication number	Publication date
CZ2000173A3 (en)	2001-05-16
UA70302C2 (uk)	2004-10-15
PE99799A1 (es)	1999-12-22
AU743269B2 (en)	2002-01-24
ZA986365B (en)	2000-01-17
EP0998291B2 (en)	2011-07-06
CN1264302A (zh)	2000-08-23
CY1107745T1 (el)	2013-04-18
CA2297115C (en)	2010-02-23
EP0998291A1 (en)	2000-05-10
DE69838066T3 (de)	2012-03-29
IL134045A0 (en)	2001-04-30
BG104139A (en)	2000-11-30
UY25103A1 (es)	2000-12-29
HK1029272A1 (en)	2001-03-30
JP2005247865A (ja)	2005-09-15
TR200000135T2 (tr)	2000-05-22
EA200000141A1 (ru)	2000-08-28
CO4940422A1 (es)	2000-07-24
NZ515555A (en)	2002-09-27
DK0998291T4 (da)	2011-09-26
DK0998291T3 (da)	2007-11-05
SI0998291T2 (sl)	2011-10-28
ID24198A (id)	2000-07-13
AR019331A2 (es)	2002-02-13
PL199125B1 (pl)	2008-08-29
EP0998291B1 (en)	2007-07-11
MY138246A (en)	2009-05-29
BR9810904A (pt)	2000-09-26
PT998291E (pt)	2007-10-11
PL338127A1 (en)	2000-09-25
CZ302668B6 (cs)	2011-08-24
AU8448798A (en)	1999-02-10
HUP0003634A2 (hu)	2001-07-30
DZ2564A1 (fr)	2003-02-15
ES2290989T3 (es)	2008-02-16
NO20000229L (no)	2000-01-17
SK602000A3 (en)	2000-07-11
SK287823B6 (sk)	2011-11-04
TW586926B (en)	2004-05-11
SK288053B6 (sk)	2013-03-01
JP2001510158A (ja)	2001-07-31
SI0998291T1 (sl)	2007-12-31
NZ501256A (en)	2002-09-27
KR20010021948A (ko)	2001-03-15
HUP0003634A3 (en)	2003-04-28
AR016768A1 (es)	2001-08-01
NZ520652A (en)	2004-06-25
NO20000229D0 (no)	2000-01-17
MA26522A1 (fr)	2004-12-20
DE69838066D1 (de)	2007-08-23
ES2290989T5 (es)	2011-11-11
OA11632A (en)	2004-11-22
WO1999003476A1 (en)	1999-01-28
IN189035B (da)	2002-12-07
AP1318A (en)	2004-10-22
AP2000001734A0 (en)	2000-03-31
DE69838066T2 (de)	2008-03-20
EA003303B1 (ru)	2003-04-24
CA2297115A1 (en)	1999-01-28
GB9715306D0 (en)	1997-09-24
HU229119B1 (en)	2013-08-28
ATE366577T1 (de)	2007-08-15
KR100680667B1 (ko)	2007-02-09
BG64892B1 (bg)	2006-08-31

Legal Events

Date	Code	Title	Description
2018-08-13	MK1K	Patent expired

Publication	Publication Date	Title
NO324993B1 (no)	2008-01-14	Kombinasjon av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)-etoksy]benzyl]tiazolidin-2,4-dion og metformin samt anvendelse derav og farmasoytisk blanding.
JP2005213273A (ja)	2005-08-11	チアゾリジンジオン、インスリン分泌促進薬およびジグアニドを用いる糖尿病の治療
JP2005247865A (ja)	2005-09-15	チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療
AU8449098A (en)	1999-02-10	Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
BG109397A (bg)	2006-05-31	Лечение на диабет с тиазолидиндион и сулфонилуреа
EP1128845A1 (en)	2001-09-05	Combinations comprising a beta-agonist and a further antdiabetic agent
BG103966A (bg)	2000-07-31	Лечение на диабет с тиазолидиндион и инхибитор наалфа глюкозидазата
US20040122060A1 (en)	2004-06-24	Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
US20040176420A1 (en)	2004-09-09	Treatment of diabetes with thiazolidinedione and sulphonylurea
MXPA00000655A (en)	2001-11-21	Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
US20030073644A1 (en)	2003-04-17	Combinations comprising a beta-agonist and a further antidiabetic agent
MXPA00000633A (en)	2001-11-21	Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
MXPA00000631A (en)	2001-11-21	Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020052324A1 (en)	2002-05-02	Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
KR20010024482A (ko)	2001-03-26	고혈당증 치료용 티아졸리딘디온의 용도
MXPA99012091A (en)	2001-12-04	Treatment of diabetes with thiazolidinedione and sulphonylurea
MXPA99012098A (en)	2000-08-01	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
MXPA01004826A (en)	2002-06-05	Combinations comprising a beta-agonist and a further antidiabetic agent
KR20010024481A (ko)	2001-03-26	고혈당증 치료용 티아졸리딘디온의 용도
MXPA00003633A (en)	2001-07-31	Use of thiazolidinediones for the treatment of hyperglycaemia